This book is devoted to innovative medicine, comprising the proceedings of the Uehara Memorial Foundation Symposium 2014. It remains extremely rare for the findings of basic research to be developed into clinical applications, and it takes a long time for the process to be achieved. The task of advancing the development of basic research into clinical reality lies with translational science, yet the field seems to struggle to find a way to move forward. To create innovative medical technology, many steps need to be taken: development and analysis of optimal animal models of human diseases,…mehr
This book is devoted to innovative medicine, comprising the proceedings of the Uehara Memorial Foundation Symposium 2014. It remains extremely rare for the findings of basic research to be developed into clinical applications, and it takes a long time for the process to be achieved. The task of advancing the development of basic research into clinical reality lies with translational science, yet the field seems to struggle to find a way to move forward. To create innovative medical technology, many steps need to be taken: development and analysis of optimal animal models of human diseases, elucidation of genomic and epidemiological data, and establishment of "proof of concept". There is also considerable demand for progress in drug research, new surgical procedures, and new clinical devices and equipment. While the original research target may be rare diseases, it is also important to apply those findings more broadly to common diseases. The book covers a wide range of topicsand isorganized into three complementary parts. The first part is basic research for innovative medicine, the second is translational research for innovative medicine, and the third is new technology for innovative medicine. This book helps to understand innovative medicine and to make progress in its realization.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
Part I Basic Research for Innovative Medicine.- 1. Diverting Glycolysis to Combat Oxidative Stress.- 2. Metabolic Regulation by Nuclear Receptors.- 3. Fighting Fire with Fire in Cancer.- 4. Linear Polyubiquitination: a Crucial Regulator of NF-kB Activation.- 5. VCP, a major ATPase in the cells, as a novel drug target for currently incurable disorders.- 6. Roles of E-cadherin in hepatocarcinogenesis.- 7. The Hippo Signaling Pathway: A Candidate New Drug Target for Malignant Tumors.- 8. Inhibitory immunoreceptors on mast cells in allergy and inflammation.- 9. Doxycycline-inducible Autoimmune Blistering Skin Disease Model.- 10. T-cell Senescence and Autoimmunity.- Part II Translational Research for Innovative Medicine .- 11. IL-6: A new era for the treatment of autoimmune inflammatory diseases.- 12. Pathogenesis of Non-alcoholic Steatohepatitis and Its Potential Therapeutic Strategies.- 13. Multifaceted translational approach of major mental illness.- 14. Translational researchof leptin in lipodystrophy and its related diseases.- 15. Translational research of the activation of the C-type natriuretic peptide (CNP)-guanylyl cyclase-B pathway for skeletal dysplasia.- 16. Clarity and Challenges in Tissue Fibrosis.- 17. TRP Channels: Their Function and Potentiality as Drug Targets.- 18. Autophagic Cell Death and Cancer Chemotherapeutics.- 19. Adrenomedullin as a Potential Therapeutic Agent for Refractory Ulcerative Colitis.- 20. RNA activation.- Part III New Technology for
Innovative Medicine.- 21. Cardiac Reprogramming for Heart Repair.- 22. Development of a new in vivo optical probe for biological diagnosis and therapy.- 23. Introduction of mesenchymal stem cells for liver surgery (hepatectomy and transplantation).- 24. Synaptic and axonal plasticity induction in the human cerebral cortex.- 25. TIM-3 is a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.- 26. TGF-beta LAP degradation products, a novel biomarker and promising therapeutic target for liver fibrogenesis.- 27. Cell-based regenerative therapy for liver disease.
Part I Basic Research for Innovative Medicine.- 1. Diverting Glycolysis to Combat Oxidative Stress.- 2. Metabolic Regulation by Nuclear Receptors.- 3. Fighting Fire with Fire in Cancer.- 4. Linear Polyubiquitination: a Crucial Regulator of NF-kB Activation.- 5. VCP, a major ATPase in the cells, as a novel drug target for currently incurable disorders.- 6. Roles of E-cadherin in hepatocarcinogenesis.- 7. The Hippo Signaling Pathway: A Candidate New Drug Target for Malignant Tumors.- 8. Inhibitory immunoreceptors on mast cells in allergy and inflammation.- 9. Doxycycline-inducible Autoimmune Blistering Skin Disease Model.- 10. T-cell Senescence and Autoimmunity.- Part II Translational Research for Innovative Medicine .- 11. IL-6: A new era for the treatment of autoimmune inflammatory diseases.- 12. Pathogenesis of Non-alcoholic Steatohepatitis and Its Potential Therapeutic Strategies.- 13. Multifaceted translational approach of major mental illness.- 14. Translational researchof leptin in lipodystrophy and its related diseases.- 15. Translational research of the activation of the C-type natriuretic peptide (CNP)-guanylyl cyclase-B pathway for skeletal dysplasia.- 16. Clarity and Challenges in Tissue Fibrosis.- 17. TRP Channels: Their Function and Potentiality as Drug Targets.- 18. Autophagic Cell Death and Cancer Chemotherapeutics.- 19. Adrenomedullin as a Potential Therapeutic Agent for Refractory Ulcerative Colitis.- 20. RNA activation.- Part III New Technology for
Innovative Medicine.- 21. Cardiac Reprogramming for Heart Repair.- 22. Development of a new in vivo optical probe for biological diagnosis and therapy.- 23. Introduction of mesenchymal stem cells for liver surgery (hepatectomy and transplantation).- 24. Synaptic and axonal plasticity induction in the human cerebral cortex.- 25. TIM-3 is a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.- 26. TGF-beta LAP degradation products, a novel biomarker and promising therapeutic target for liver fibrogenesis.- 27. Cell-based regenerative therapy for liver disease.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826